The DOI matches its Crossref record; 275 of the 275 references it cites were found in a registry or an index.
Active immunization against cancer with dendritic cells: The near future
Abstract
DCs are antigen-presenting cells that regulate several components of the immune system. The mature or terminal stage of DC development induces specific T-cell immunity and resistance to experimental tumors in vivo. However, DC maturation is induced by inflammatory and microbial stimuli, so it is unlikely that mature DCs normally present antigens from tumor cells in cancer patients. Accordingly, clinical studies have begun in which DCs are generated ex vivo, charged with tumor antigens, exposed to maturation stimuli and reinfused to immunize patients. This approach has the potential to control responses to cancer antigens in a specific and nontoxic manner, in both vaccination and therapeutic settings. DCs can mobilize several immune resistance mechanisms. These include CD8+ CTLs, CD4+ helper T cells, NK and NKT cells. Each of these lymphocytes recognizes targets through a distinct mechanism and has the capacity to kill tumor cells and release valuable protective cytokines like IFN-γ. CD4+ T cells also provide essential help for the expansion and maintenance of CD8+ cytolytic cells, while NK and NKT cells can eliminate targets that dampen presentation on MHC class I to escape CTL recognition. The stimulation and concerted action of these classes of lymphocytes can now be studied directly in patients, using ex vivo–derived DCs. Several findings have emerged from studies of healthy volunteers who have been immunized with DCs charged with model antigens, KLH protein and influenza virus matrix peptide. Mature DCs elicit a polarized Th1 type of CD4 T-cell response, only a single injection being required. Vaccination with antigen-bearing DCs also markedly improves the functional affinity of CD8+ T cells. These findings are important in the context of immunotherapy because Th1 cells are more efficient helper cells in experimental models of viral infection and tumors, while high-affinity CTLs should improve recognition of tumor-derived peptides. An important caution also has surfaced when DCs are not adequately differentiated. Immature DCs can silence adaptive T-cell responses, e.g., by inducing IL-10–producing, T-reg cells. DC-based active immunization does not result in major short-term toxicity in healthy subjects or cancer patients. Tumor-specific T-cell responses have been induced and detected in fresh blood specimens without the need for restimulation in vitro. However, the immune responses observed in the first protocols are still smaller than those seen naturally in acute viral infections. Occasional clinical regressions have been noted in these initial feasibility studies, particularly in melanomas, pediatric tumors, lymphomas, prostate cancers and renal cell cancers. This information, coupled with progress in DC biology, suggests many ways to improve the efficacy of this new therapy. Some relevant topics include antigen loading and DC maturation procedures, frequency and route of DC injection, efficiency of DC homing to lymphoid tissues and their longevity once there and the role of distinct DC subsets. A valuable positive control in active immunization protocols is to include an aliquot of DCs pulsed with a viral peptide to verify that the DCs and the patient's immune system are measurably competent. Most of the first vaccination protocols have used DCs charged with synthetic, HLA-binding tumor peptides. Many methods are in place to allow DCs to process a broader array of peptides appropriate for the patient's MHC haplotype. These include transfection (RNA, DNA and viral vectors), select pathways of adsorptive endocytosis, exosomes and tumor cell fusion. An intriguing new approach involves the processing of whole tumor cells. Immature DCs are able to internalize tumor cells, including melanoma, EBV lymphoma and prostate carcinoma cell lines. Following maturation, the processing of tumor cells leads to presentation of multiple epitopes on both MHC class I and II products of DCs. Basic issues in human cancer immunology can be investigated with ex vivo–based DC immunization. Some topics for the near future are the extent to which tumor-specific tolerance is an obstacle to immune therapy and the need to mobilize several adaptive and innate mechanisms in tandem, including Th1 type CD4+ helper T, NK and NKT cells. Progress is also being made in manipulating DCs directly in vivo. This will help to design vaccine adjuvants that improve presentation of tumor cells in patients. Although tumors challenge the immune system in formidable ways relative to infectious diseases, it is now feasible to use active immunotherapy and DC biology to manipulate and study the human response to cancer. CTL, cytolytic T lymphocyte; DC, dendritic cell; EBV, Epstein-Barr virus; KAR, killer activating receptor; KIR, killer inhibitory receptor; KLH, keyhole limpet hemocyanin; MAb, monoclonal antibody; NK, natural killer; NKT cell, natural killer T cell; ODN, oligodeoxynucleotide; TRAIL, TNF-related apoptosis-inducing ligand; TRANCE, TNF-
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–275 of 275
Schuler-Thurner, B., Dieckmann, D., Keikavoussi, P., Bender, A., Maczek, C., Jonuleit, H., Röder, C., Haendle, I., Leisgang, W., Dunbar, R., et al. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.6.3492 · Cited by 200
Dhodapkar, M. V., Krasovsky, J., Steinman, R. M., & Bhardwaj, N. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9051 · Cited by 196
Self-citationCd40-Independent Pathways of T Cell Help for Priming of Cd8+ Cytotoxic T Lymphocytes
Lu, Z., Yuan, L., Zhou, X., Sotomayor, E., Levitsky, H. I., & Pardoll, D. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.3.541 · Cited by 196
Cerwenka, A., Morgan, T. M., Harmsen, A. G., & Dutton, R. W. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.2.423 · Cited by 195
Del Prete, G. F., De Carli, M., Ricci, M., & Romagnani, S. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.4.809 · Cited by 194
Brunner, C., Seiderer, J., Schlamp, A., Bidlingmaier, M., Eigler, A., Haimerl, W., Lehr, H.-A., Krieg, A. M., Hartmann, G., & Endres, S. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.11.6278 · Cited by 192
Schuurhuis, D. H., Laban, S., Toes, R. E. M., Ricciardi-Castagnoli, P., Kleijmeer, M. J., van der Voort, E. I. H., Rea, D., Offringa, R., Geuze, H. J., Melief, C. J. M., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.1.145 · Cited by 192
Panelli, M. C., Wunderlich, J., Jeffries, J., Wang, E., Mixon, A., Rosenberg, S. A., & Marincola, F. M. (2000) · Journal of Immunotherapy · doi:10.1097/00002371-200007000-00013 · Cited by 180
Viral vectors for dendritic cell-based immunotherapy
Jenne, L., Schuler, G., & Steinkasserer, A. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(00)01813-5 · Cited by 180
Recognition of autologous dendritic cells by human NK cells
Carbone, E., Terrazzano, G., Ruggiero, G., Zanzi, D., Ottaiano, A., Manzo, C., Kärre, K., & Zappacosta, S. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199912)29:12<4022::aid-immu4022>3.0.co;2-o · Cited by 178
Dendritic cells up-regulate immunoproteasomes and the proteasome regulator PA28 during maturation
Macagno, A., Gilliet, M., Sallusto, F., Lanzavecchia, A., Nestle, F. O., & Groettrup, M. (1999) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199912)29:12<4037::aid-immu4037>3.0.co;2-t · Cited by 174
Morgan, D. J., Kreuwel, H. T. C., & Sherman, L. A. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.2.723 · Cited by 172
Hiltbold, E. M., Vlad, A. M., Ciborowski, P., Watkins, S. C., & Finn, O. J. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.7.3730 · Cited by 165
Sparwasser, T., Vabulas, R. M., Villmow, B., Lipford, G. B., & Wagner, H. (2000) · European Journal of Immunology · doi:10.1002/1521-4141(200012)30:12<3591::aid-immu3591>3.0.co;2-j · Cited by 165
Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma
Lim, S. H., & Bailey-Wood, R. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19991008)83:2<215::aid-ijc12>3.0.co;2-q · Cited by 163
Lodge, P. A., Jones, L. A., Bader, R. A., Murphy, G. P., & Salgaller, M. L. (2000) · PubMed · Cited by 160
Jonuleit, H., Wiedemann, K., Müller, G., Degwert, J., Hoppe, U., Knop, J., & Enk, A. H. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.6.2610 · Cited by 159
Feuerstein, B., Berger, T. G., Maczek, C., Röder, C., Schreiner, D., Hirsch, U., Haendle, I., Leisgang, W., Glaser, A., Kuss, O., et al. (2000) · Journal of Immunological Methods · doi:10.1016/s0022-1759(00)00269-6 · Cited by 159
Jenne, L., Arrighi, J.-F., Jonuleit, H., Saurat, J. ‐., & Hauser, C. (2000) · PubMed · Cited by 159
Ebner, S., Ratzinger, G., Krösbacher, B., Schmuth, M., Weiss, A., Reider, D., Kroczek, R. A., Herold, M., Heufler, C., Fritsch, P. O., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.633 · Cited by 156
Herr, W., Ranieri, E., Olson, W. C., Zarour, H. M., Gesualdo, L., & Storkus, W. J. (2000) · Blood · doi:10.1182/blood.v96.5.1857 · Cited by 153
Flores‐Romo, L., Björck, P., Duvert, V., van Kooten, C., Saeland, S., & Banchereau, J. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.2.341 · Cited by 152
Follow the Leader: NK Cell Receptors for Classical and Nonclassical MHC Class I
Lanier, L. L. (1998) · Cell · doi:10.1016/s0092-8674(00)81398-7 · Cited by 150
Russo, V. E. A., Tanzarella, S., Dalerba, P. D., Rigatti, D., Rovere, P. Q., Villa, A., Bordignon, C., & Traversari, C. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.040540197 · Cited by 146
CD47 Engagement Inhibits Cytokine Production and Maturation of Human Dendritic Cells
Demeure, C. E., Tanaka, H., Mateo, V., Rubio, M., Delespesse, G., & Sarfati, M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.4.2193 · Cited by 145
Dyall, J., Latouche, J., Schnell, S., & Sadelain, M. (2001) · Blood · doi:10.1182/blood.v97.1.114 · Cited by 144
Dubey, P., Hendrickson, R. C., Meredith, S. C., Siegel, C., Shabanowitz, J., Skipper, J., Engelhard, V. H., Hunt, D. F., & Schreiber, H. W. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.4.695 · Cited by 143
Liso, A., Stockerl-Goldstein, K. E., Auffermann-Gretzinger, S., Benike, C. J., Reichardt, V. L., van Beckhoven, A., Rajapaksa, R., Engleman, E. G., Blume, K. G., & Levy, R. (2000) · Transplantation and Cellular Therapy · doi:10.1016/s1083-8791(00)70027-9 · Cited by 142
Sogn, J. A. (1998) · Immunity · doi:10.1016/s1074-7613(00)80641-x · Cited by 140
The Role of Aquaporins in Dendritic Cell Macropinocytosis
de Baey, A., & Lanzavecchia, A. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.4.743 · Cited by 138
Strobel, I., Berchtold, S., Götze, A., Schulze, U., Schuler, G., & Steinkasserer, A. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301326 · Cited by 138
Haicheur, N., Bismuth, E., Bosset, S., Adotévi, O., Warnier, G., Lacabanne, V., Régnault, A., Desaymard, C., Amigorena, S., Ricciardi‐Castagnoli, P., et al. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.6.3301 · Cited by 131
EBNA1-specific CD4+ T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function
Bickham, K. L., Münz, C., Tsang, M. L., Larsson, M., Fonteneau, J., Bhardwaj, N., & Steinman, R. M. (2001) · Journal of Clinical Investigation · doi:10.1172/jci10209 · Cited by 128
Self-citationCandido, K. A., Shimizu, K., McLaughlin, J. C., Kunkel, R., Fuller, J. A., Redman, B. G., Thomas, E. K., Nickoloff, B. J., & Mulé, J. J. (2001) · PubMed · Cited by 124
CD4 + T cell-mediated control of a γ-herpesvirus in B cell-deficient mice is mediated by IFN-γ
Christensen, J. P., Cardin, R. D., Branum, K. C., & Doherty, P. C. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.9.5135 · Cited by 123
Vabulas, R. M., Pircher, H., Lipford, G. B., Häcker, H., & Wagner, H. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.5.2372 · Cited by 123
The dendritic cell and human cancer vaccines
Dallal, R. M., & Lotze, M. T. (2000) · Current Opinion in Immunology · doi:10.1016/s0952-7915(00)00146-1 · Cited by 120
Henderson, R. A., Nimgaonkar, M. T., Watkins, S. C., Robbins, P. D., Ball, E. D., & Finn, O. J. (1996) · PubMed · Cited by 118
Subklewe, M. S., Paludan, C., Tsang, M. L., Mahnke, K., Steinman, R. M., & Münz, C. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.3.405 · Cited by 117
Self-citationRNA-transfected dendritic cells in cancer immunotherapy
Mitchell, D. A., & Nair, S. K. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11405 · Cited by 112
Ignatius, R., Marovich, M., Mehlhop, E., Villamide, L., Mahnke, K., Cox, W. I., Isdell, F., Frankel, S. S., Mascola, J. R., Steinman, R. M., et al. (2000) · Journal of Virology · doi:10.1128/jvi.74.23.11329-11338.2000 · Cited by 107
Self-citationFerlazzo, G., Wesa, A. K., Wei, W., & Galy, A. H. M. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.7.3597 · Cited by 104
The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides
Weiner, G. J. (2000) · Journal of Leukocyte Biology · doi:10.1189/jlb.68.4.455 · Cited by 104
Treatment of solid tumours in children with tumour-lysate-pulsed dendritic cells
Geiger, J. D., Hutchinson, R. J., Hohenkirk, L., McKenna, E., Chang, A. E., & Mulé, J. J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02762-8 · Cited by 103
Yang, D., Howard, O. M. Z., Chen, Q., & Oppenheim, J. J. (1999) · PubMed · Cited by 103
Gatti, E., Velleca, M., Biedermann, B. C., Ma, W., Unternaehrer, J., Ebersold, M. W., Medzhitov, R. M., Pober, J. S., & Mellman, I. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.7.3600 · Cited by 102
Efficient nonviral transfection of dendritic cells and their use for in vivo immunization
Irvine, A. S., Trinder, P. K. E., Laughton, D. L., Ketteringham, H., McDermott, R. H., Reid, S. C. H., Haines, A. M. R., Amir, A., Husain, R. D., Doshi, R., et al. (2000) · Nature Biotechnology · doi:10.1038/82383 · Cited by 98
Cd4+ T Cell Subsets during Virus Infection
Maloy, K. J., Burkhart, C., Junt, T., Odermatt, B., Oxenius, A., Piali, L., Zinkernagel, R. M., & Hengartner, H. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.191.12.2159 · Cited by 94
Jakob, T., Walker, P., Krieg, A. Μ., von Stebut, E., Udey, M. C., & Vogel, J. C. (1999) · International Archives of Allergy and Immunology · doi:10.1159/000024163 · Cited by 93
Kuniyoshi, J., Kuniyoshi, C., Lim, A. M., Wang, F. Y., Bade, E., Lau, R., Thomas, E. K., & Weber, J. S. (1999) · Cellular Immunology · doi:10.1006/cimm.1999.1469 · Cited by 91
Assessing Cd8 T Cell Number and Dysfunction in the Presence of Antigen
Welsh, R. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.5.f19 · Cited by 91
Mature Dendritic Cells Respond to SDF-1, but not to Several β-Chemokines
Delgado, E., Finkel, V., Baggiolini, M., Mackay, C. R., Steinman, R. M., & Granelli‐Piperno, A. (1998) · Immunobiology · doi:10.1016/s0171-2985(98)80073-9 · Cited by 88
Self-citationCervical cancer vaccines: Emerging concepts and developments
Silva, D. M. D., Eiben, G. L., Fausch, S. C., Wakabayashi, M. T., Rudolf, M. P., Velders, M. P., & Kast, W. M. (2001) · Journal of Cellular Physiology · doi:10.1002/1097-4652(200102)186:2<169::aid-jcp1023>3.0.co;2-h · Cited by 88
Role of dendritic cells in the induction and maintenance of autoimmune diseases
Ludewig, B., Odermati, B., Ochsenbein, A. F., Zinkemagel, R. M., & Hengortner, H. (1999) · Immunological Reviews · doi:10.1111/j.1600-065x.1999.tb01305.x · Cited by 88
Arnold, D., Wahl, C., Faath, S., Rammensee, H., & Schild, H. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.3.461 · Cited by 87
Chapoval, A. I., Tamada, K., & Chen, L. (2000) · Blood · doi:10.1182/blood.v95.7.2346 · Cited by 82
APC Stimulated by CpG Oligodeoxynucleotide Enhance Activation of MHC Class I-Restricted T Cells
Warren, T. L., Bhatia, S. K., Acosta, A. M., Dahle, C. E., Ratliff, T. L., Krieg, A. Μ., & Weiner, G. J. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.11.6244 · Cited by 82
Peripheral tolerance of CD4 T cells following local activation in adolescent mice
Förster, I., & Lieberam, I. (1996) · European Journal of Immunology · doi:10.1002/eji.1830261253 · Cited by 82
Serody, J. S., Collins, E. J., Tisch, R., Kuhns, J. J., & Frelinger, J. A. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.9.4961 · Cited by 79
Engelmayer, J., Larsson, M., Lee, A. W.-T., Lee, M., Cox, W. I., Steinman, R. M., & Bhardwaj, N. (2001) · Journal of Virology · doi:10.1128/jvi.75.5.2142-2153.2001 · Cited by 79
Self-citationSubklewe, M. S., Chahroudi, A., Schmaljohn, A. L., Kurilla, M. G., Bhardwaj, N., & Steinman, R. M. (1999) · Blood · doi:10.1182/blood.v94.4.1372 · Cited by 75
Self-citationCellular Interactions Involved in Th Cell Memory
van Essen, D., Dullforce, P. A., Brocker, T., & Gray, D. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.7.3640 · Cited by 74
Murphy, G. P., Tjoa, B. A., Simmons, S. J., Rogers, M., Kenny, G. M., & Jarisch, J. (2000) · The Prostate · Cited by 69
Accessing Epstein-Barr Virus-Specific T-Cell Memory with Peptide-Loaded Dendritic Cells
Redchenko, I., & Rickinson, A. B. (1999) · Journal of Virology · doi:10.1128/jvi.73.1.334-342.1999 · Cited by 69
Schnell, S., Young, J. W., Houghton, A. N., & Sadelain, M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.3.1243 · Cited by 65
Terheyden, P. A. M., Straten, P. T., Bröcker, E., Kämpgen, E., & Becker, J. C. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.12.6633 · Cited by 54
Dendritic cells or their exosomes are effective biotherapies of cancer
Zitvogel, L., Fernandez, N. C., Lozier, A., Wolfers, J., Régnault, A., Raposo, G., & Amigorena, S. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00090-8 · Cited by 48
Strobel, I., Krumbholz, M., Menke, A., Hoffmann, E., Dunbar, P. R., Bender, A., Hobom, G., Steinkasserer, A., Schuler, G., & Grassmann, R. (2000) · Human Gene Therapy · doi:10.1089/104303400750035735 · Cited by 39
Dendritic Cell-Based Immunotherapy of Renal Cell Carcinoma
Biyani, C. S., Mackay, A. M., Sissions, G., Pettersson, B., Scarpa, R. M., de Lisa, A., Porru, D., Usai, E., Morita, T., Tachikawa, N., et al. (1998) · Urologia Internationalis · doi:10.1159/000030291 · Cited by 38
You, Z., Huang, X. F., Hester, J. H., Rollins, L. A., Rooney, C. M., & Chen, S. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.8.4581 · Cited by 37
Autologous Dendritic Cells for Treatment of Advanced Cancer — An Update
Schadendorf, D., & Nestle, F. O. (2001) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-59537-0_24 · Cited by 36
Paucity of functional T-cell memory to melanoma antigens in healthy donors and melanoma patients.
Dhodapkar, M. V., Young, J. W., Chapman, P. B., Cox, W. I., Fonteneau, J., Amigorena, S., Houghton, A. N., Steinman, R. M., & Bhardwaj, N. (2000) · PubMed · Cited by 34
Self-citationChen, B., Stiff, P. J., Sloan, G. J., Kash, J. J., Manjunath, R., Pathasarathy, M., Oldenburg, D., Foreman, K. E., & Nickoloff, B. J. (2001) · Clinical Immunology · doi:10.1006/clim.2000.4968 · Cited by 28
Present difficulties and future promise of MHC multimers in autoimmune exploration
Ferlin, W. G., Glaichenhaus, N., & Mougneau, E. (2000) · Current Opinion in Immunology · doi:10.1016/s0952-7915(00)00161-8 · Cited by 20
Bischof, A. (2000) · doi:10.1002/1521-4141(200003)30:3
Cited by
Escudier, B., Dorval, T., Chaput, N., André, F., Caby, M.-P., Novault, S., Flament, C., Leboulaire, C., Borg, C., Amigorena, S., et al. (2005) · Journal of Translational Medicine · doi:10.1186/1479-5876-3-10 · Cited by 1,280
Systemic effects of local radiotherapy
Formenti, S. C., & Demaria, S. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70082-8 · Cited by 1,021
The use of dendritic cells in cancer immunotherapy
Schuler, G., Schuler-Thurner, B., & Steinman, R. M. (2003) · Current Opinion in Immunology · doi:10.1016/s0952-7915(03)00015-3 · Cited by 631
Self-citationHuman lung cancer cells express functionally active Toll-like receptor 9
Droemann, D., Albrecht, D., Gerdes, J., Ulmer, A. J., Branscheid, D., Vollmer, E., Dalhoff, K., Zabel, P., & Goldmann, T. (2005) · Respiratory Research · doi:10.1186/1465-9921-6-1 · Cited by 340
Banerjee, D. K., Dhodapkar, M. V., Matayeva, E., Steinman, R. M., & Dhodapkar, K. M. (2006) · Blood · doi:10.1182/blood-2006-03-011353 · Cited by 311
Self-citation
Metadata
- Authors
- Steinman, R. M., & Dhodapkar, M.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2001-11-15
- Volume
- 94
- Issue
- 4
- Pages
- 459-473
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2000749507
- Cited by
- 299
- References
- 275
- FWCI
- 12.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.